XEN-901
- Generic Name
- XEN-901
Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 82
- Registration Number
- NCT05493293
- Locations
- ๐ช๐ธ
Neurocrine Clinical Site, Valencia, Spain
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
Phase 2
- Conditions
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
- Interventions
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 52
- Registration Number
- NCT05226780
- Locations
- ๐บ๐ธ
UCSF Medical Center, San Francisco, California, United States
๐บ๐ธCook Children's Medical Center, Fort Worth, Texas, United States
๐บ๐ธUniversity of Rochester, Rochester, New York, United States
A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures
Phase 2
Completed
- Conditions
- Focal Onset SeizureFocal Onset Epilepsy
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 101
- Registration Number
- NCT05159908
- Locations
- ๐ช๐ธ
Neurocrine Clinical Site, Valencia, Spain
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
Phase 2
Active, not recruiting
- Conditions
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 52
- Registration Number
- NCT04873869
- Locations
- ๐บ๐ธ
UCSF Medical Center, San Francisco, California, United States
๐บ๐ธChildren's National Hospital, Washington, District of Columbia, United States
๐บ๐ธAnn & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: Inert Ingredients Oral Product
- First Posted Date
- 2018-03-15
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Xenon Pharmaceuticals Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT03467100
- Locations
- ๐ฌ๐ง
Quotient Sciences, Ruddington, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath